Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

Right arrow Help viewing high resolution images
Right arrow Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.



Figure 2 Infarct size as a percentage of the area at risk (AAR). Sarpogrelate (SG) pretreated group: SG was infused at a rate of 5 or 10 mg/kg/h starting 10 min before ischemia until 20 min after reperfusion for 60 min. Sarpogrelate post-treated group: SG was infused at a rate of 10 mg/kg/h starting 10 min before reperfusion until 50 min after reperfusion for 60 min. Sarpogrelate (5 and 10 mg/kg/h) reduced the infarct size, which was blocked by a selective protein kinase C inhibitor, chelerythrine, or a mitochondrial adenosine triphosphate sensitive potassium channel blocker, 5-hydroxydecanoate (5-HD). Chelerythrine or 5-HD alone did not affect the infarct size. *p < 0.05 versus control.





Right arrow Return to article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement